Intravitreal Brolucizumab for Choroidal Neovascularization Associated to Angioid Streaks

Chakraborty, Somnath; Sheth, Jay

doi:10.1155/2022/3442306

Cited by 2 publications

(3 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Narrative Review Findingsmentioning

confidence: 99%

“…The authors of this review article also found one single case report of a case with CNV secondary to ASs that was treated successfully with one single dose of intravitreal brolucizumab [ 171 ]. However, as the authors of this article acknowledge, this is a retrospective single-case report with limited follow-up [ 171 ]. Therefore, larger prospective studies will be required to elucidate the safety and efficacy of brolucizumab in the treatment of CNV secondary to ASs [ 171 ].…”

Section: Narrative Review Findingsmentioning

confidence: 99%

“…However, as the authors of this article acknowledge, this is a retrospective single-case report with limited follow-up [ 171 ]. Therefore, larger prospective studies will be required to elucidate the safety and efficacy of brolucizumab in the treatment of CNV secondary to ASs [ 171 ].…”

Section: Narrative Review Findingsmentioning

confidence: 99%

See 2 more Smart Citations

Angioid Streaks Remain a Challenge in Diagnosis, Management, and Treatment

Tsokolas,

Tossounis,

Tyradellis

et al. 2024

Vision

View full text Add to dashboard Cite

Aim: Angioid streaks (ASs) are a rare retinal condition and compromise visual acuity when complicated with choroidal neovascularization (CNV). They represent crack-like dehiscences at the level of the Bruch’s membrane. This objective narrative review aims to provide an overview of pathophysiology, current treatment modalities, and future perspectives on this condition. Materials and Methods: A literature search was performed using “PubMed”, “Web of Science”, “Scopus”, “ScienceDirect”, “Google Scholar”, “medRxiv”, and “bioRxiv.” Results: ASs may be idiopathic, but they are also associated with systemic conditions, such as pseudoxanthoma elasticum, hereditary hemoglobinopathies, or Paget’s disease. Currently, the main treatment is the use of anti-vascular endothelial growth factors (anti-VEGF) to treat secondary CNV, which is the major complication observed in this condition. If CNV is detected and treated promptly, patients with ASs have a good chance of maintaining functional vision. Other treatment modalities have been tried but have shown limited benefit and, therefore, have not managed to be more widely accepted. Conclusion: In summary, although there is no definitive cure yet, the use of anti-VEGF treatment for secondary CNV has provided the opportunity to maintain functional vision in individuals with AS, provided that CNV is detected and treated early.

show abstract

Section: Narrative Review Findingsmentioning

confidence: 99%